Free Trial
NASDAQ:SMMT

Summit Therapeutics (SMMT) Stock Price, News & Analysis

Summit Therapeutics logo
$18.54 +1.02 (+5.82%)
(As of 12/6/2024 06:15 PM ET)

About Summit Therapeutics Stock (NASDAQ:SMMT)

Key Stats

Today's Range
$17.61
$19.30
50-Day Range
$17.52
$23.46
52-Week Range
$2.05
$33.89
Volume
2.20 million shs
Average Volume
1.81 million shs
Market Capitalization
$13.67 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.00
Consensus Rating
Moderate Buy

Company Overview

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Summit Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
77th Percentile Overall Score

SMMT MarketRank™: 

Summit Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 256th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Summit Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Summit Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Summit Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Summit Therapeutics are expected to decrease in the coming year, from ($0.30) to ($0.33) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Summit Therapeutics is -66.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Summit Therapeutics is -66.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Summit Therapeutics has a P/B Ratio of 168.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.17% of the outstanding shares of Summit Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Summit Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Summit Therapeutics has recently decreased by 6.16%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Summit Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Summit Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.17% of the outstanding shares of Summit Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Summit Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Summit Therapeutics has recently decreased by 6.16%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Summit Therapeutics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Summit Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    32 people have searched for SMMT on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    Only 25 people have added Summit Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Summit Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    88.30% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 4.61% of the stock of Summit Therapeutics is held by institutions.

  • Read more about Summit Therapeutics' insider trading history.
Receive SMMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMMT Stock News Headlines

Financial markets news icon
MarketBeat Week in Review – 11/4 - 11/8 (SMMT)
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts
We recommended Palantir in 2021, now we’re recommending this...
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
3 Monster Stocks in the Making
See More Headlines

SMMT Stock Analysis - Frequently Asked Questions

Summit Therapeutics' stock was trading at $2.61 at the start of the year. Since then, SMMT shares have increased by 610.3% and is now trading at $18.54.
View the best growth stocks for 2024 here
.

Summit Therapeutics Inc. (NASDAQ:SMMT) posted its quarterly earnings data on Monday, November, 15th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.09. The firm had revenue of $6.12 million for the quarter.

Summit Therapeutics (SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

Summit Therapeutics' top institutional investors include Baker BROS. Advisors LP (3.31%), FMR LLC (1.13%), State Street Corp (0.47%) and Geode Capital Management LLC (0.42%). Insiders that own company stock include Robert W Duggan, Ankur Dhingra and Mahkam Zanganeh.
View institutional ownership trends
.

Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Summit Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
11/15/2021
Today
12/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SMMT
Employees
105
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.00
High Stock Price Target
$44.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+83.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-614,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$700,000.00
Price / Sales
19,531.84
Book Value
$0.11 per share

Miscellaneous

Free Float
86,281,000
Market Cap
$13.67 billion
Optionable
Optionable
Beta
-0.92

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:SMMT) was last updated on 12/8/2024 by MarketBeat.com Staff
From Our Partners